MX2020000213A - Novel composition of enzalutamide oral dosage form and method of manufacturing thereof. - Google Patents

Novel composition of enzalutamide oral dosage form and method of manufacturing thereof.

Info

Publication number
MX2020000213A
MX2020000213A MX2020000213A MX2020000213A MX2020000213A MX 2020000213 A MX2020000213 A MX 2020000213A MX 2020000213 A MX2020000213 A MX 2020000213A MX 2020000213 A MX2020000213 A MX 2020000213A MX 2020000213 A MX2020000213 A MX 2020000213A
Authority
MX
Mexico
Prior art keywords
enzalutamide
manufacturing
dosage form
oral dosage
novel composition
Prior art date
Application number
MX2020000213A
Other languages
Spanish (es)
Inventor
Mahendrabhai Shah Dharmesh
Manappa Badiger Aravind
Ketanbhai Choksi Rakshit
Naginbhai Patel Bhavesh
Sharad Salunkhe Piyusha
Ramnivedan Soni Niraj
Original Assignee
Bdr Pharmaceuticals International Private Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=64950639&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2020000213(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bdr Pharmaceuticals International Private Ltd filed Critical Bdr Pharmaceuticals International Private Ltd
Publication of MX2020000213A publication Critical patent/MX2020000213A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to novel composition of oral dosage forms of enzalutamide with pharmaceutically acceptable excipients and method of manufacturing thereof. The invention provides economical and advanced dosage form.
MX2020000213A 2017-07-04 2017-11-21 Novel composition of enzalutamide oral dosage form and method of manufacturing thereof. MX2020000213A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201721023465 2017-07-04
PCT/IB2017/057273 WO2019008426A1 (en) 2017-07-04 2017-11-21 Novel composition of enzalutamide oral dosage form and method of manufacturing thereof

Publications (1)

Publication Number Publication Date
MX2020000213A true MX2020000213A (en) 2020-08-17

Family

ID=64950639

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020000213A MX2020000213A (en) 2017-07-04 2017-11-21 Novel composition of enzalutamide oral dosage form and method of manufacturing thereof.

Country Status (7)

Country Link
BR (1) BR112020000207A2 (en)
CL (1) CL2020000017A1 (en)
MX (1) MX2020000213A (en)
PH (1) PH12020500045A1 (en)
RU (1) RU2020105102A (en)
WO (1) WO2019008426A1 (en)
ZA (1) ZA202000609B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR118925A1 (en) * 2020-05-13 2021-11-10 Novocap S A CONCENTRATED LIQUID SOLUTION OF NON-STEROID ANTIANDROGENS AND PROCEDURE FOR PREPARING THE SOLUTION

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160346207A1 (en) * 2014-02-05 2016-12-01 Lek Pharmaceuticals D.D. Solid Pharmaceutical Compositions Of Androgen Receptor Antagonists

Also Published As

Publication number Publication date
ZA202000609B (en) 2021-08-25
WO2019008426A1 (en) 2019-01-10
CL2020000017A1 (en) 2020-05-22
RU2020105102A (en) 2021-08-04
BR112020000207A2 (en) 2020-07-07
PH12020500045A1 (en) 2020-11-09

Similar Documents

Publication Publication Date Title
MX2018007704A (en) Pharmaceutical composition comprising amorphous lenalidomide and an antioxidant.
SG10201804868PA (en) Compounds for the inhibition of indoleamine-2,3-dioxygenase
MY196319A (en) Polycyclic TLR7/8 Antagonists and use Thereof in the Treatment of Immune Disorders
IL273959A (en) Methods and compositions for the treatment of rare diseases
MX2015010921A (en) Carbazole compounds useful as bromodomain inhibitors.
EA201690962A1 (en) COMPOSITIONS
EP3705118A4 (en) Oral solid dosage form composition having improved disintegration and preparation method therefor
MX2017008386A (en) Site specific dosing of a btk inhibitor.
TR201821116A2 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING POSACONAZOL AND THE MANUFACTURING METHOD
IN2013MU03583A (en)
SG10201902203VA (en) Eutectic formulations of cyclobenzaprine hydrochloride
PH12016501686A1 (en) Pharmaceutical compositions of sitagliptin
IN2014MU00303A (en)
EA201691918A1 (en) PHARMACEUTICAL COMPOSITIONS OF KINAZ INHIBITOR KINAZ OF THE RAF FAMILY, METHODS OF THEIR PRODUCTION AND METHODS OF THEIR USE
MX2017015137A (en) Once daily oral pharmaceutical composition of isotretinoin.
MX2018012618A (en) Oral pharmaceutical compositions of mesalazine.
EA201791009A1 (en) COMPOSITIONS CONTAINING CYCLOSPORIN
CR20210158A (en) Vitamin d pediatric dosage forms, methods of making and using
MX2019001634A (en) Amide compounds, pharmaceutical compositions thereof, and methods of using the same.
MX2021002322A (en) Novel methods.
MX2021003862A (en) Crystalline forms and processes of lenvatinib besylate.
TR201721505A2 (en) The combination comprising linagliptin and metformin
MX2015000179A (en) Itraconazole compositions and dosage forms, and methods of using the same.
MX2017008983A (en) Sulfonamide pharmaceutical composition.
PH12020500045A1 (en) Novel composition of enzalutamide oral dosage form and method of manufacturing thereof